New diabetes drug shows promise in first human tests
NCT ID NCT05363774
First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 24 times
Summary
This early-stage study tested a new medicine, NNC0519-0130, in 161 people to see if it is safe and how it works in the body. The medicine aims to lower blood sugar and reduce appetite, which could help people with type 2 diabetes and overweight. Participants received either the medicine or a placebo as injections or tablets for up to 18 weeks. The study is complete, and results will guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS (DIABETES MELLITUS, TYPE 2) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novo Nordisk Investigational Site
Søborg, 2860, Denmark
-
Profil GmbH & Co. KG
Mainz, 55116, Germany
-
Profil Institut für Stoffwechselforschung GmbH
Neuss, 41460, Germany
Conditions
Explore the condition pages connected to this study.